Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.

IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2024-11-06 DOI:10.1177/13524585241293363
Laura Witt, Sabrina Haben, Karen Dost-Kovalsky, Natalia Friedmann, Nadine Bast, Theresa Oganowski, Ralf Gold, Sandra Thiel, Kerstin Hellwig
{"title":"Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.","authors":"Laura Witt, Sabrina Haben, Karen Dost-Kovalsky, Natalia Friedmann, Nadine Bast, Theresa Oganowski, Ralf Gold, Sandra Thiel, Kerstin Hellwig","doi":"10.1177/13524585241293363","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Information on symptomatic therapy (ST) use in women of childbearing age with multiple sclerosis is sparse, and data on the impact of ST pregnancy exposure on pregnancy outcome are lacking.</p><p><strong>Objective: </strong>To investigate (1) ST use patterns pre-conception, during pregnancy and postpartum and (2) pregnancy outcomes.</p><p><strong>Methods: </strong>Pregnancy data from the German Multiple Sclerosis and Pregnancy Registry were analyzed for the ST use from pre-conception to postpartum. Pregnancy outcomes were compared between ST-exposed (<i>n</i> = 282) and matched (disease modifying therapy and age) ST-naive (n = 536) pregnancies.</p><p><strong>Results: </strong>Of 2,449 pregnancies, 1,053 (43.0%) received ST anytime between pre-conception and postpartum, 282 (11.5%) at pre-conception and during pregnancy. The most commonly used drug classes were antidepressants (24.8%), analgetics (31.0%), and anticonvulsives (8.7%). Exposure to ST during pregnancy did not result in an increased incidence of adverse pregnancy outcomes, major congenital abnormalities, or pregnancy complications.</p><p><strong>Conclusion: </strong>Nearly 50% of women used ST between pre-conception and postpartum, but only 12% pre-conception and during pregnancy. ST use during pregnancy did not adversely affect pregnancy outcomes in our cohort. More data are needed to analyze the effect of ST on pregnancy and fetal outcomes stratified by drug to improve recommendations for ST use in family planning.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241293363"},"PeriodicalIF":4.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241293363","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Information on symptomatic therapy (ST) use in women of childbearing age with multiple sclerosis is sparse, and data on the impact of ST pregnancy exposure on pregnancy outcome are lacking.

Objective: To investigate (1) ST use patterns pre-conception, during pregnancy and postpartum and (2) pregnancy outcomes.

Methods: Pregnancy data from the German Multiple Sclerosis and Pregnancy Registry were analyzed for the ST use from pre-conception to postpartum. Pregnancy outcomes were compared between ST-exposed (n = 282) and matched (disease modifying therapy and age) ST-naive (n = 536) pregnancies.

Results: Of 2,449 pregnancies, 1,053 (43.0%) received ST anytime between pre-conception and postpartum, 282 (11.5%) at pre-conception and during pregnancy. The most commonly used drug classes were antidepressants (24.8%), analgetics (31.0%), and anticonvulsives (8.7%). Exposure to ST during pregnancy did not result in an increased incidence of adverse pregnancy outcomes, major congenital abnormalities, or pregnancy complications.

Conclusion: Nearly 50% of women used ST between pre-conception and postpartum, but only 12% pre-conception and during pregnancy. ST use during pregnancy did not adversely affect pregnancy outcomes in our cohort. More data are needed to analyze the effect of ST on pregnancy and fetal outcomes stratified by drug to improve recommendations for ST use in family planning.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
有症状的多发性硬化症治疗对妊娠结局的影响。
背景:有关多发性硬化症育龄妇女使用对症治疗(ST)的信息很少,也缺乏有关ST妊娠暴露对妊娠结局影响的数据:目的:调查(1)孕前、孕期和产后使用 ST 的模式;(2)妊娠结局:方法:对德国多发性硬化症和妊娠登记处的妊娠数据进行分析,了解从孕前到产后使用 ST 的情况。结果:在 2,449 例妊娠中,2,449 例妊娠的妊娠结局为:(1)妊娠期间:(2)妊娠结局:(3)妊娠期间:(4)妊娠结局:(5)妊娠期间:(6)妊娠结局:在 2,449 名孕妇中,1,053 人(43.0%)在孕前和产后随时接受 ST 治疗,282 人(11.5%)在孕前和孕期接受 ST 治疗。最常用的药物类别是抗抑郁药(24.8%)、镇痛药(31.0%)和抗惊厥药(8.7%)。孕期接触 ST 并未导致不良妊娠结局、重大先天畸形或妊娠并发症的发生率增加:近 50%的妇女在孕前和产后使用 ST,但只有 12%的妇女在孕前和孕期使用 ST。在我们的队列中,怀孕期间使用 ST 不会对妊娠结局产生不良影响。需要更多的数据来分析ST对妊娠和胎儿结局的影响,并根据药物进行分层,以改进在计划生育中使用ST的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Multiple Sclerosis Journal
Multiple Sclerosis Journal 医学-临床神经学
CiteScore
10.90
自引率
6.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585
期刊最新文献
Cryptogenic organising pneumonia in patients treated with ocrelizumab. Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review. Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study. Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies. Development and initial validation of the Cognitive Change Scale (CCS).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1